Literature DB >> 15308933

Is postcontrast trueFISP imaging advantageous?

Bettina Jung1, Gabriele A Krombach, Rolf W Günther, Arno Buecker.   

Abstract

RATIONALE AND
OBJECTIVES: Contrast of trueFISP images depends mainly on the T2/T1 ratio. Consequently, there is a potential gain in signal intensity after administration of paramagnetic contrast medium despite the strong T2 weighting. The purpose of this study was to analyze signal intensities of abdominal organs after applying contrast medium and to determine whether this yields an improved contrast for pathologies compared with precontrast trueFISP.
MATERIALS AND METHODS: Fifty patients underwent an abdominal examination, including the trueFISP sequence before and after the administration of contrast medium. All images were obtained with a 1.5 T system. The mean signal-to-noise ratio before and after contrast medium was assessed for abdominal organs, vessels, muscle, and fat. The contrast-to-noise ratio (CNR) of pathologic lesions was calculated.
RESULTS: The trueFISP sequence yielded a higher signal-to-noise ratio after application of contrast medium for all organs except for fat and the aorta. CNR of solid lesions (angiomyolipoma, liver adenoma, liver hemangioma, hepatocellular carcinoma) increased whereas contrast of cysts decreased.
CONCLUSIONS: TrueFISP imaging after application of contrast medium led to better CNR for many solid lesions while cysts showed a diminished contrast. We advise trueFISP imaging sequences before and after contrast medium application.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15308933     DOI: 10.1097/01.rli.0000131476.52176.44

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  1 in total

1.  Evaluation of steady state free precession imaging of the pancreas.

Authors:  Christoph U Herborn; Florian M Vogt; Thomas C Lauenstein; Mathias Goyen; Jörg F Debatin; Stefan G Ruehm
Journal:  Eur Radiol       Date:  2005-04-20       Impact factor: 5.315

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.